Gemcitabine's Antiretroviral Activity Against Murine Leukemia Virus
Author Information
Author(s): Christine L. Clouser, Colleen M. Holtz, Mary Mullett, Duane L. Crankshaw, Jacquie E. Briggs, Jay Chauhan, Ilze Matise VanHoutan, Steven E. Patterson, Louis M. Mansky
Primary Institution: University of Minnesota
Hypothesis
Gemcitabine would be an alternative to hydroxyurea that could be translated to clinical use for the treatment of retroviral infections when used in combination with current anti-retroviral therapies.
Conclusion
Gemcitabine has potent antiretroviral activity in vivo and ex vivo using the LP-BM5 MuLV model.
Supporting Evidence
- Gemcitabine decreased MuLV infectivity in cell culture with an EC50 in the low nanomolar range.
- Treatment with gemcitabine decreased spleen size and plasma IgM levels in infected mice.
- Gemcitabine was effective at doses as low as 1 mg/kg/day without detectable toxicity.
Takeaway
Gemcitabine is a medicine that can help fight certain viruses without making you sick, and it works better than some older medicines.
Methodology
The study examined gemcitabine's effects on MuLV in cell culture and in C57Bl/6 mice infected with LP-BM5 MuLV.
Potential Biases
Potential bias in the selection of treatment doses and the small number of animals in each treatment group.
Limitations
The study was limited by the small sample size and variability in responses to gemcitabine among mice.
Participant Demographics
C57Bl/6 mice, aged 8-10 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website